Pharma CEOs boast of trimming headcount and boosting productivity. Spoiler alert: they're not.
Critics claim pharma is skimping on research spending - but the data say otherwise.
Should FDA automatically approve drugs available in other countries? The potential clinical benefits may be overstated.
New data on drug ramp rates could increase the financial attractiveness of “pioneer” projects.
We found 31 Phase 2 assets that could be deal targets if private biotechs can't access public capital - but only for pharmas that can stomach a little risk.
A timely test case for the math behind "value-based pricing".